Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway

Song Wu, Leilei Peng, Hongyang Sang, Qianping Li, Shaofei Cheng

Research output: Contribution to journalArticle

Abstract

Purpose: Non-small lung cancer (NSLC) is one of the leading causes of cancer-related deaths world over. Excempting operable cases the treatments for NSCLC mainly include chemotherapy and radiotherapy. However, the survival rate for NSCLC is still far from satsifactory. Moreover, chemotherapy has lot of associated side effects. Therefore, there is an urgent need to look for novel and more viable treatment options. Against this background, the present study was designed to evaluate the anticancer activity of α-Bisabolol against NSCLC. Methods: Cell viability was assessed by MTT assay. Apo-ptosis was determined by DAPI and annexin V/propidium iodide (PI) staining. Mitochondrial membrane potential (MMP) and cell cycle analysis were determined by flow cytometry. Cell migration was investigated by wound healing assay and protein expression was evaluated by western blotting.

Results: α-Bisabolol exerted significant anticancer activity on A549 NSCLC cells with IC50 of 15 μM. The anticancer effects of α-Bisabolol were found to be due to G2/M cell cycle arrest and mitochondrial apoptosis. α-Bisabolol also inhibited cell migration of A549 cells dose-dependently. Moreover, the results showed that α-Bisabolol could inhibit the PI3K/ AKT signalling pathway in a dose-dependent manner. The results of the present study indicate that α-Bisabolol exerted selective anticancer effects on A549 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. Conclusions: This molecule showed promising anticancer features and could be developed as a potent lead candidate for the management and treatment of NSCLC.

Original languageEnglish (US)
Pages (from-to)1407-1412
Number of pages6
JournalJournal of B.U.ON.
Volume23
Issue number5
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Cell Migration Inhibition
Cell Cycle Checkpoints
Non-Small Cell Lung Carcinoma
Up-Regulation
Apoptosis
Phosphatidylinositol 3-Kinases
Cell Movement
G2 Phase Cell Cycle Checkpoints
Drug Therapy
Propidium
Mitochondrial Membrane Potential
Annexin A5
Wound Healing
Inhibitory Concentration 50
bisabolol
Lung Neoplasms
Cell Survival
Cell Cycle
Flow Cytometry
Radiotherapy

Keywords

  • Apoptosis
  • Cell cycle arrest
  • Cell migration
  • Non-small lung cancer
  • PI3K/AKT
  • Α-bisabolol

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway. / Wu, Song; Peng, Leilei; Sang, Hongyang; Li, Qianping; Cheng, Shaofei.

In: Journal of B.U.ON., Vol. 23, No. 5, 01.09.2018, p. 1407-1412.

Research output: Contribution to journalArticle

@article{1d491868032a4749b909360f89d60611,
title = "Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway",
abstract = "Purpose: Non-small lung cancer (NSLC) is one of the leading causes of cancer-related deaths world over. Excempting operable cases the treatments for NSCLC mainly include chemotherapy and radiotherapy. However, the survival rate for NSCLC is still far from satsifactory. Moreover, chemotherapy has lot of associated side effects. Therefore, there is an urgent need to look for novel and more viable treatment options. Against this background, the present study was designed to evaluate the anticancer activity of α-Bisabolol against NSCLC. Methods: Cell viability was assessed by MTT assay. Apo-ptosis was determined by DAPI and annexin V/propidium iodide (PI) staining. Mitochondrial membrane potential (MMP) and cell cycle analysis were determined by flow cytometry. Cell migration was investigated by wound healing assay and protein expression was evaluated by western blotting.Results: α-Bisabolol exerted significant anticancer activity on A549 NSCLC cells with IC50 of 15 μM. The anticancer effects of α-Bisabolol were found to be due to G2/M cell cycle arrest and mitochondrial apoptosis. α-Bisabolol also inhibited cell migration of A549 cells dose-dependently. Moreover, the results showed that α-Bisabolol could inhibit the PI3K/ AKT signalling pathway in a dose-dependent manner. The results of the present study indicate that α-Bisabolol exerted selective anticancer effects on A549 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. Conclusions: This molecule showed promising anticancer features and could be developed as a potent lead candidate for the management and treatment of NSCLC.",
keywords = "Apoptosis, Cell cycle arrest, Cell migration, Non-small lung cancer, PI3K/AKT, Α-bisabolol",
author = "Song Wu and Leilei Peng and Hongyang Sang and Qianping Li and Shaofei Cheng",
year = "2018",
month = "9",
day = "1",
language = "English (US)",
volume = "23",
pages = "1407--1412",
journal = "Journal of B.U.ON.",
issn = "1107-0625",
publisher = "Balkan Union of Oncology",
number = "5",

}

TY - JOUR

T1 - Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway

AU - Wu, Song

AU - Peng, Leilei

AU - Sang, Hongyang

AU - Li, Qianping

AU - Cheng, Shaofei

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: Non-small lung cancer (NSLC) is one of the leading causes of cancer-related deaths world over. Excempting operable cases the treatments for NSCLC mainly include chemotherapy and radiotherapy. However, the survival rate for NSCLC is still far from satsifactory. Moreover, chemotherapy has lot of associated side effects. Therefore, there is an urgent need to look for novel and more viable treatment options. Against this background, the present study was designed to evaluate the anticancer activity of α-Bisabolol against NSCLC. Methods: Cell viability was assessed by MTT assay. Apo-ptosis was determined by DAPI and annexin V/propidium iodide (PI) staining. Mitochondrial membrane potential (MMP) and cell cycle analysis were determined by flow cytometry. Cell migration was investigated by wound healing assay and protein expression was evaluated by western blotting.Results: α-Bisabolol exerted significant anticancer activity on A549 NSCLC cells with IC50 of 15 μM. The anticancer effects of α-Bisabolol were found to be due to G2/M cell cycle arrest and mitochondrial apoptosis. α-Bisabolol also inhibited cell migration of A549 cells dose-dependently. Moreover, the results showed that α-Bisabolol could inhibit the PI3K/ AKT signalling pathway in a dose-dependent manner. The results of the present study indicate that α-Bisabolol exerted selective anticancer effects on A549 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. Conclusions: This molecule showed promising anticancer features and could be developed as a potent lead candidate for the management and treatment of NSCLC.

AB - Purpose: Non-small lung cancer (NSLC) is one of the leading causes of cancer-related deaths world over. Excempting operable cases the treatments for NSCLC mainly include chemotherapy and radiotherapy. However, the survival rate for NSCLC is still far from satsifactory. Moreover, chemotherapy has lot of associated side effects. Therefore, there is an urgent need to look for novel and more viable treatment options. Against this background, the present study was designed to evaluate the anticancer activity of α-Bisabolol against NSCLC. Methods: Cell viability was assessed by MTT assay. Apo-ptosis was determined by DAPI and annexin V/propidium iodide (PI) staining. Mitochondrial membrane potential (MMP) and cell cycle analysis were determined by flow cytometry. Cell migration was investigated by wound healing assay and protein expression was evaluated by western blotting.Results: α-Bisabolol exerted significant anticancer activity on A549 NSCLC cells with IC50 of 15 μM. The anticancer effects of α-Bisabolol were found to be due to G2/M cell cycle arrest and mitochondrial apoptosis. α-Bisabolol also inhibited cell migration of A549 cells dose-dependently. Moreover, the results showed that α-Bisabolol could inhibit the PI3K/ AKT signalling pathway in a dose-dependent manner. The results of the present study indicate that α-Bisabolol exerted selective anticancer effects on A549 cells via induction of cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. Conclusions: This molecule showed promising anticancer features and could be developed as a potent lead candidate for the management and treatment of NSCLC.

KW - Apoptosis

KW - Cell cycle arrest

KW - Cell migration

KW - Non-small lung cancer

KW - PI3K/AKT

KW - Α-bisabolol

UR - http://www.scopus.com/inward/record.url?scp=85053248416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053248416&partnerID=8YFLogxK

M3 - Article

C2 - 30570866

AN - SCOPUS:85053248416

VL - 23

SP - 1407

EP - 1412

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - 5

ER -